- Home
- NTES vs REGN Comparison
NTES vs REGN Comparison
Compare NTES & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTES
- REGN
- Stock Information
- Founded
- NTES 1997
- REGN 1988
- Country
- NTES China
- REGN United States
- Employees
- NTES N/A
- REGN N/A
- Industry
- NTES Computer Software: Prepackaged Software
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- NTES Technology
- REGN Health Care
- Exchange
- NTES Nasdaq
- REGN Nasdaq
- Market Cap
- NTES 78.0B
- REGN 63.4B
- IPO Year
- NTES 2000
- REGN 1991
- Fundamental
- Price
- NTES $132.85
- REGN $547.36
- Analyst Decision
- NTES Strong Buy
- REGN Buy
- Analyst Count
- NTES 7
- REGN 22
- Target Price
- NTES $117.86
- REGN $839.91
- AVG Volume (30 Days)
- NTES 819.7K
- REGN 1.2M
- Earning Date
- NTES 08-21-2025
- REGN 08-01-2025
- Dividend Yield
- NTES 2.07%
- REGN 0.64%
- EPS Growth
- NTES 7.67
- REGN 16.49
- EPS
- NTES 1.38
- REGN 39.43
- Revenue
- NTES $14,782,889,829.00
- REGN $14,085,700,000.00
- Revenue This Year
- NTES $11.09
- REGN N/A
- Revenue Next Year
- NTES $6.92
- REGN $6.78
- P/E Ratio
- NTES $19.00
- REGN $13.88
- Revenue Growth
- NTES 1.90
- REGN 7.52
- 52 Week Low
- NTES $75.85
- REGN $476.49
- 52 Week High
- NTES $135.32
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- NTES 61.96
- REGN 57.41
- Support Level
- NTES $131.78
- REGN $514.79
- Resistance Level
- NTES $135.32
- REGN $531.21
- Average True Range (ATR)
- NTES 1.59
- REGN 13.62
- MACD
- NTES -0.51
- REGN 6.38
- Stochastic Oscillator
- NTES 68.05
- REGN 96.86
About NTES NetEase Inc.
Founded in the late 1990s as an internet portal, NetEase has transformed into a leading force in the second-largest online game company gaming in China. While its initial success was built upon the massively multiplayer online role-playing game Fantasy Westward Journey, NetEase has expanded its portfolio with captivating franchises that resonate with both domestic and international players. Over the past decade, the company has created titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which maintain significant player bases today. Beyond in-house development, the company also collaborates with likes of Microsoft and Marvel to create and publish games based on renowned IPs, including World of Warcraft, Diablo Immortal, and Marvel Rivals.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).